WallStSmart

Becton Dickinson and Company (BDX)vsUtah Medical Products Inc (UTMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 56816% more annual revenue ($21.92B vs $38.52M). UTMD leads profitability with a 29.3% profit margin vs 8.0%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

UTMD

Hold

48

out of 100

Grade: D+

Growth: 2.0Profit: 8.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued
UTMDSignificantly Overvalued (-173.3%)

Margin of Safety

-173.3%

Fair Value

$23.32

Current Price

$63.71

$40.39 premium

UndervaluedFair: $23.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

UTMD3 strengths · Avg: 9.0/10
Operating MarginProfitability
31.1%10/10

Strong operational efficiency at 31.1%

Profit MarginProfitability
29.3%9/10

Keeps 29 of every $100 in revenue as profit

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

UTMD4 concerns · Avg: 2.3/10
Market CapQuality
$204.39M3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.252/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-6.4%2/10

Earnings declined 6.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : UTMD

The strongest argument for UTMD centers on Operating Margin, Profit Margin, Price/Book. Profitability is solid with margins at 29.3% and operating margin at 31.1%.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : UTMD

The primary concerns for UTMD are Market Cap, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

BDX profiles as a value stock while UTMD is a declining play — different risk/reward profiles.

UTMD carries more volatility with a beta of 0.32 — expect wider price swings.

BDX is growing revenue faster at 1.6% — sustainability is the question.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Utah Medical Products Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.

Want to dig deeper into these stocks?